Limits...
Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma.

Broadhead ML, Lokmic Z, Tan ML, Stevenson A, Binns DS, Cullinane C, Hicks RJ, Choong PF, Myers DE - Front Surg (2015)

Bottom Line: Treatment agent [pigment epithelium-derived factor (PEDF)] was delivered to the peritoneal cavity.Primary tumors and metastases were evaluated by in vivo bioluminescent assays, micro-computed tomography, [(18)F]-Fluoride-PET and [(18)F]-FDG-PET. [(18)F]-Fluoride-PET was more sensitive than [(18)F]-FDG-PET for detecting early disease.Both [(18)F]-Fluoride-PET and [(18)F]-FDG-PET showed progressive disease in the model, with fourfold and twofold increases in standardized uptake value (p < 0.05) by the study endpoint, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, St. Vincent's Hospital Melbourne, University of Melbourne , Fitzroy, VIC , Australia.

ABSTRACT

Introduction: Reliable animal models are required to evaluate novel treatments for osteosarcoma. In this study, the aim was to implement advanced imaging techniques in a murine model of orthotopic osteosarcoma to improve disease modeling and the assessment of primary and metastatic disease.

Materials and methods: Intra-tibial injection of luciferase-tagged OPGR80 murine osteosarcoma cells was performed in Balb/c nude mice. Treatment agent [pigment epithelium-derived factor (PEDF)] was delivered to the peritoneal cavity. Primary tumors and metastases were evaluated by in vivo bioluminescent assays, micro-computed tomography, [(18)F]-Fluoride-PET and [(18)F]-FDG-PET.

Results: [(18)F]-Fluoride-PET was more sensitive than [(18)F]-FDG-PET for detecting early disease. Both [(18)F]-Fluoride-PET and [(18)F]-FDG-PET showed progressive disease in the model, with fourfold and twofold increases in standardized uptake value (p < 0.05) by the study endpoint, respectively. In vivo bioluminescent assay showed that systemically delivered PEDF inhibited growth of primary osteosarcoma.

Discussion: Application of [(18)F]-Fluoride-PET and [(18)F]-FDG-PET to an established murine model of orthotopic osteosarcoma has improved the assessment of disease. The use of targeted imaging should prove beneficial for the evaluation of new approaches to osteosarcoma therapy.

No MeSH data available.


Related in: MedlinePlus

MTS proliferation assay. OPGR80 cell proliferation was inhibited by treatment with PEDF in vitro.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4522961&req=5

Figure 1: MTS proliferation assay. OPGR80 cell proliferation was inhibited by treatment with PEDF in vitro.

Mentions: MTS proliferation assay was performed to examine the effects of PEDF on osteosarcoma cell proliferation in vitro. Proliferation of OPGR80 cells was inhibited by PEDF treatment in a concentration-dependent manner. Across the range of tested concentrations (1.56, 3.125, 6.25, 12.5, 25, 50, 100 nM), maximal inhibition was achieved by 100 nM PEDF treatment, with a 28.7 ± 3.56% reduction in absorption ratio demonstrated (p < 0.01) (Figure 1).


Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma.

Broadhead ML, Lokmic Z, Tan ML, Stevenson A, Binns DS, Cullinane C, Hicks RJ, Choong PF, Myers DE - Front Surg (2015)

MTS proliferation assay. OPGR80 cell proliferation was inhibited by treatment with PEDF in vitro.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4522961&req=5

Figure 1: MTS proliferation assay. OPGR80 cell proliferation was inhibited by treatment with PEDF in vitro.
Mentions: MTS proliferation assay was performed to examine the effects of PEDF on osteosarcoma cell proliferation in vitro. Proliferation of OPGR80 cells was inhibited by PEDF treatment in a concentration-dependent manner. Across the range of tested concentrations (1.56, 3.125, 6.25, 12.5, 25, 50, 100 nM), maximal inhibition was achieved by 100 nM PEDF treatment, with a 28.7 ± 3.56% reduction in absorption ratio demonstrated (p < 0.01) (Figure 1).

Bottom Line: Treatment agent [pigment epithelium-derived factor (PEDF)] was delivered to the peritoneal cavity.Primary tumors and metastases were evaluated by in vivo bioluminescent assays, micro-computed tomography, [(18)F]-Fluoride-PET and [(18)F]-FDG-PET. [(18)F]-Fluoride-PET was more sensitive than [(18)F]-FDG-PET for detecting early disease.Both [(18)F]-Fluoride-PET and [(18)F]-FDG-PET showed progressive disease in the model, with fourfold and twofold increases in standardized uptake value (p < 0.05) by the study endpoint, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, St. Vincent's Hospital Melbourne, University of Melbourne , Fitzroy, VIC , Australia.

ABSTRACT

Introduction: Reliable animal models are required to evaluate novel treatments for osteosarcoma. In this study, the aim was to implement advanced imaging techniques in a murine model of orthotopic osteosarcoma to improve disease modeling and the assessment of primary and metastatic disease.

Materials and methods: Intra-tibial injection of luciferase-tagged OPGR80 murine osteosarcoma cells was performed in Balb/c nude mice. Treatment agent [pigment epithelium-derived factor (PEDF)] was delivered to the peritoneal cavity. Primary tumors and metastases were evaluated by in vivo bioluminescent assays, micro-computed tomography, [(18)F]-Fluoride-PET and [(18)F]-FDG-PET.

Results: [(18)F]-Fluoride-PET was more sensitive than [(18)F]-FDG-PET for detecting early disease. Both [(18)F]-Fluoride-PET and [(18)F]-FDG-PET showed progressive disease in the model, with fourfold and twofold increases in standardized uptake value (p < 0.05) by the study endpoint, respectively. In vivo bioluminescent assay showed that systemically delivered PEDF inhibited growth of primary osteosarcoma.

Discussion: Application of [(18)F]-Fluoride-PET and [(18)F]-FDG-PET to an established murine model of orthotopic osteosarcoma has improved the assessment of disease. The use of targeted imaging should prove beneficial for the evaluation of new approaches to osteosarcoma therapy.

No MeSH data available.


Related in: MedlinePlus